The Utility of 99mTc Depreotide Compared with F-18 Fluorodeoxyglucose Positron Emission Tomography and Surgical Staging in Patients with Suspected Non-small Cell Lung Cancer

Daniel Kahn, Yusuf Menda, Kemp Kernstine, David Bushnell, Kelley McLaughlin, Sara Miller, Kevin Berbaum

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Study objectives: The findings from conventional imaging modalities, such as chest CT, are frequently unreliable in patients with lung cancer. This study was designed to compare the relative diagnostic accuracies and utility of the two most widely used functional imaging examinations, F-18-2-fluoro2- deoxyglucose (FDG) positron emission tomography (PET) and 99mTc depreotide scintigraphy, for the diagnosis and staging of lung cancer. Design: Prospective, experimental investigation. Setting: Academic medical center. Patients: One hundred sixty-six subjects with suspected lung cancer were enrolled in the study. Interventions: Whole-body and single-photon emission CT imaging of the chest was performed after IV administration of 99mTc depreotide. Attenuation-corrected FDG PET imaging was performed after IV administration of FDG. Image findings were compared with the biopsy results or clinical follow-up. Measurements and results: In 157 subjects with evaluable lung lesions, the sensitivities and specificities for detecting malignant disease (95% confidence intervals) of FDG PET are 96% (90 to 98%) and 71% (54 to 85%), and of 99mTc depreotide are 94% (88 to 98%) and 51% (34 to 68%). In the 139 subjects with available complete staging data, FDG PET correctly staged 76 of 139 patients (55%), and 99mTc depreotide correctly staged 63 of 139 patients (45%). Conclusions: The sensitivity for detection of lung cancer in the primary lesion is equally high for FDG PET and 99mTc depreotide. The specificity is superior for FDG PET. The staging accuracy of FDG PET and 99mTc depreotide is similar, but when read with the chest CT neither scintigraphic examination is sufficiently accurate to stage patients with non-small cell lung cancer.

Original languageEnglish (US)
Pages (from-to)494-501
Number of pages8
JournalChest
Volume125
Issue number2
DOIs
StatePublished - Feb 2004

Fingerprint

Fluorodeoxyglucose F18
Deoxyglucose
Non-Small Cell Lung Carcinoma
Positron-Emission Tomography
Lung Neoplasms
Thorax
Photons
Radionuclide Imaging
Research Design
Confidence Intervals
Biopsy
Sensitivity and Specificity
Lung

Keywords

  • Tc depreotide
  • Lung cancer
  • Positron emission tomography
  • Scintigraphy

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

The Utility of 99mTc Depreotide Compared with F-18 Fluorodeoxyglucose Positron Emission Tomography and Surgical Staging in Patients with Suspected Non-small Cell Lung Cancer. / Kahn, Daniel; Menda, Yusuf; Kernstine, Kemp; Bushnell, David; McLaughlin, Kelley; Miller, Sara; Berbaum, Kevin.

In: Chest, Vol. 125, No. 2, 02.2004, p. 494-501.

Research output: Contribution to journalArticle

Kahn, Daniel ; Menda, Yusuf ; Kernstine, Kemp ; Bushnell, David ; McLaughlin, Kelley ; Miller, Sara ; Berbaum, Kevin. / The Utility of 99mTc Depreotide Compared with F-18 Fluorodeoxyglucose Positron Emission Tomography and Surgical Staging in Patients with Suspected Non-small Cell Lung Cancer. In: Chest. 2004 ; Vol. 125, No. 2. pp. 494-501.
@article{fc459dc73c274a489c46f10c126570e4,
title = "The Utility of 99mTc Depreotide Compared with F-18 Fluorodeoxyglucose Positron Emission Tomography and Surgical Staging in Patients with Suspected Non-small Cell Lung Cancer",
abstract = "Study objectives: The findings from conventional imaging modalities, such as chest CT, are frequently unreliable in patients with lung cancer. This study was designed to compare the relative diagnostic accuracies and utility of the two most widely used functional imaging examinations, F-18-2-fluoro2- deoxyglucose (FDG) positron emission tomography (PET) and 99mTc depreotide scintigraphy, for the diagnosis and staging of lung cancer. Design: Prospective, experimental investigation. Setting: Academic medical center. Patients: One hundred sixty-six subjects with suspected lung cancer were enrolled in the study. Interventions: Whole-body and single-photon emission CT imaging of the chest was performed after IV administration of 99mTc depreotide. Attenuation-corrected FDG PET imaging was performed after IV administration of FDG. Image findings were compared with the biopsy results or clinical follow-up. Measurements and results: In 157 subjects with evaluable lung lesions, the sensitivities and specificities for detecting malignant disease (95{\%} confidence intervals) of FDG PET are 96{\%} (90 to 98{\%}) and 71{\%} (54 to 85{\%}), and of 99mTc depreotide are 94{\%} (88 to 98{\%}) and 51{\%} (34 to 68{\%}). In the 139 subjects with available complete staging data, FDG PET correctly staged 76 of 139 patients (55{\%}), and 99mTc depreotide correctly staged 63 of 139 patients (45{\%}). Conclusions: The sensitivity for detection of lung cancer in the primary lesion is equally high for FDG PET and 99mTc depreotide. The specificity is superior for FDG PET. The staging accuracy of FDG PET and 99mTc depreotide is similar, but when read with the chest CT neither scintigraphic examination is sufficiently accurate to stage patients with non-small cell lung cancer.",
keywords = "Tc depreotide, Lung cancer, Positron emission tomography, Scintigraphy",
author = "Daniel Kahn and Yusuf Menda and Kemp Kernstine and David Bushnell and Kelley McLaughlin and Sara Miller and Kevin Berbaum",
year = "2004",
month = "2",
doi = "10.1378/chest.125.2.494",
language = "English (US)",
volume = "125",
pages = "494--501",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "2",

}

TY - JOUR

T1 - The Utility of 99mTc Depreotide Compared with F-18 Fluorodeoxyglucose Positron Emission Tomography and Surgical Staging in Patients with Suspected Non-small Cell Lung Cancer

AU - Kahn, Daniel

AU - Menda, Yusuf

AU - Kernstine, Kemp

AU - Bushnell, David

AU - McLaughlin, Kelley

AU - Miller, Sara

AU - Berbaum, Kevin

PY - 2004/2

Y1 - 2004/2

N2 - Study objectives: The findings from conventional imaging modalities, such as chest CT, are frequently unreliable in patients with lung cancer. This study was designed to compare the relative diagnostic accuracies and utility of the two most widely used functional imaging examinations, F-18-2-fluoro2- deoxyglucose (FDG) positron emission tomography (PET) and 99mTc depreotide scintigraphy, for the diagnosis and staging of lung cancer. Design: Prospective, experimental investigation. Setting: Academic medical center. Patients: One hundred sixty-six subjects with suspected lung cancer were enrolled in the study. Interventions: Whole-body and single-photon emission CT imaging of the chest was performed after IV administration of 99mTc depreotide. Attenuation-corrected FDG PET imaging was performed after IV administration of FDG. Image findings were compared with the biopsy results or clinical follow-up. Measurements and results: In 157 subjects with evaluable lung lesions, the sensitivities and specificities for detecting malignant disease (95% confidence intervals) of FDG PET are 96% (90 to 98%) and 71% (54 to 85%), and of 99mTc depreotide are 94% (88 to 98%) and 51% (34 to 68%). In the 139 subjects with available complete staging data, FDG PET correctly staged 76 of 139 patients (55%), and 99mTc depreotide correctly staged 63 of 139 patients (45%). Conclusions: The sensitivity for detection of lung cancer in the primary lesion is equally high for FDG PET and 99mTc depreotide. The specificity is superior for FDG PET. The staging accuracy of FDG PET and 99mTc depreotide is similar, but when read with the chest CT neither scintigraphic examination is sufficiently accurate to stage patients with non-small cell lung cancer.

AB - Study objectives: The findings from conventional imaging modalities, such as chest CT, are frequently unreliable in patients with lung cancer. This study was designed to compare the relative diagnostic accuracies and utility of the two most widely used functional imaging examinations, F-18-2-fluoro2- deoxyglucose (FDG) positron emission tomography (PET) and 99mTc depreotide scintigraphy, for the diagnosis and staging of lung cancer. Design: Prospective, experimental investigation. Setting: Academic medical center. Patients: One hundred sixty-six subjects with suspected lung cancer were enrolled in the study. Interventions: Whole-body and single-photon emission CT imaging of the chest was performed after IV administration of 99mTc depreotide. Attenuation-corrected FDG PET imaging was performed after IV administration of FDG. Image findings were compared with the biopsy results or clinical follow-up. Measurements and results: In 157 subjects with evaluable lung lesions, the sensitivities and specificities for detecting malignant disease (95% confidence intervals) of FDG PET are 96% (90 to 98%) and 71% (54 to 85%), and of 99mTc depreotide are 94% (88 to 98%) and 51% (34 to 68%). In the 139 subjects with available complete staging data, FDG PET correctly staged 76 of 139 patients (55%), and 99mTc depreotide correctly staged 63 of 139 patients (45%). Conclusions: The sensitivity for detection of lung cancer in the primary lesion is equally high for FDG PET and 99mTc depreotide. The specificity is superior for FDG PET. The staging accuracy of FDG PET and 99mTc depreotide is similar, but when read with the chest CT neither scintigraphic examination is sufficiently accurate to stage patients with non-small cell lung cancer.

KW - Tc depreotide

KW - Lung cancer

KW - Positron emission tomography

KW - Scintigraphy

UR - http://www.scopus.com/inward/record.url?scp=1242276355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1242276355&partnerID=8YFLogxK

U2 - 10.1378/chest.125.2.494

DO - 10.1378/chest.125.2.494

M3 - Article

VL - 125

SP - 494

EP - 501

JO - Chest

JF - Chest

SN - 0012-3692

IS - 2

ER -